Abstract: Provided are methods for producing compositions comprising a population of cardiomyocytes enriched for or substantially devoid of sinoatrial node-like pacemaker cardiomyocytes (SANLCM) from human pluripotent stem cells (hPSCs), and methods of use thereof.
Abstract: The present invention is directed to methods and compositions for identifying targets for induction of self-tolerance and treatment of autoimmune disease.
Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.
Type:
Grant
Filed:
February 21, 2019
Date of Patent:
January 7, 2020
Assignees:
Regeneron Pharmaceuticals, Inc., University Health Network
Inventors:
Lisa Arleen Purcell, Sarah J. Higgins, Kevin C. Kain
Abstract: Methods for the treatment of cancer using double negative (DN) T cells are described. The DNTs may be used for the treatment of chemotherapy-resistant cancers such as recurring or relapsing acute myeloid leukemia (AML). The use of allogenic DNTs, such as those derived from healthy donors, that do not exhibit toxicity towards normal host tissues and the complications associated with graft-versus-host-disease, is also described.
Abstract: Described are various embodiments of an acoustic upper airway assessment system and method, and sleep apnea assessment system and method relying thereon. In one embodiment, a non-invasive method is described for assessing upper airway anatomy in a subject while breathing. This method comprises receiving as input at a hardware processor a digital signal representative of respiratory sounds generated by the subject while breathing; isolating digital respiratory sound segments from said digital signal; computationally extracting a designated spectral feature from each of said segments to characterize said respiratory sounds within each of said segments; automatically evaluating each said extracted spectral feature against a preset upper airway anatomy metric associated with said designated spectral feature to characterize a given upper airway anatomy measure in the subject while breathing; and outputting a sleep apnea severity indication based on said characterized upper airway anatomy measure.
Type:
Grant
Filed:
May 31, 2016
Date of Patent:
December 17, 2019
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Azadeh Yadollahi, Frank Rudzicz, Shumit Saha
Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
Type:
Grant
Filed:
June 23, 2016
Date of Patent:
December 10, 2019
Assignee:
University Health Network
Inventors:
Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Grant
Filed:
January 3, 2018
Date of Patent:
December 3, 2019
Assignees:
PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
Inventors:
Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Abstract: Embodiments disclose a method performed by at least one processor for processing a plurality of x-ray projection images of a subject, the method comprising a plurality of operations including reconstructing the projection images to yield a volume reconstruction; segmenting the reconstructed volume by assigning a material type to each voxel; estimating a first set of scatter images corresponding to a subset of the projection images by calculating probabilistic predictions of interactions of x-rays with the subject and applying a low pass spatial filter to the scatter images; estimating a second set of scatter images corresponding to projection images not included in the subset, based on the first set of scatter images; and subtracting, for each projection image, the corresponding scatter image to yield a corrected projection image.
Type:
Grant
Filed:
December 18, 2014
Date of Patent:
December 3, 2019
Assignees:
Elekta AB (publ), University Health Network
Inventors:
Marcus Hennix, Hakan Nordstrom, Markus Eriksson, Jonas Adler, David Jaffray, Gregory Bootsma, Frank Verhaegen, Bjorn Nutti
Abstract: Methods and systems for evaluating a proposed treatment plan for radiation therapy, for evaluating one or more delineated regions of interest for radiation therapy, and/or for generating a proposed treatment plan for radiation therapy. Machine learning based on historical data may be used.
Type:
Grant
Filed:
June 12, 2014
Date of Patent:
November 12, 2019
Assignee:
University Health Network
Inventors:
Thomas G. Purdie, Christopher James McIntosh, Igor Svistoun
Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
Type:
Grant
Filed:
April 19, 2019
Date of Patent:
November 12, 2019
Assignee:
University Health Network
Inventors:
Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Grant
Filed:
July 2, 2016
Date of Patent:
November 5, 2019
Assignees:
PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
Inventors:
Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Abstract: The present invention relates to in vitro methods of enriching populations of human pluripotent stem cells that are induced to differentiate to cardiomyocyte progenitor cells and cardiomyocyte cells. The cell populations can be enriched by isolating cells that express SIRPA. The invention also related to in vitro-enriched populations of cardiomyocyte cells and cardiomyocyte progenitor cells obtained from populations of pluripotent stem.
Type:
Application
Filed:
May 11, 2018
Publication date:
October 24, 2019
Applicant:
UNIVERSITY HEALTH NETWORK
Inventors:
Gordon Keller, April M. Craft, Nicole C. Dubois
Abstract: Various embodiments are described herein for a system and a method for identifying a region of interest in tissue using mass spectrometry. An agent administration component can be provided to administer an exogenous agent to the tissue. A sampling unit can also be provided to acquire a sample from the tissue. The sample can then be provided to a high sensitivity analysis platform, such as a mass analyzer, to analyze the sample and determine a distribution of the exogenous agent or a by-product of the exogenous agent within the tissue based on the analysis. The analysis platform can then identify the region of interest based on the distribution of the exogenous agent or the distribution of the by-product.
Type:
Grant
Filed:
December 8, 2015
Date of Patent:
October 15, 2019
Assignee:
University Health Network
Inventors:
Arash Zarrine-Afsar, David Anthony Jaffray
Abstract: Systems and methods for determining bacterial load in targets and tracking changes in bacterial load of targets over time are disclosed. An autofluorescence detection and collection device includes a light source configured to directly illuminate at least a portion of a target and an area around the target with excitation light causing at least one biomarker in the illuminated target to fluoresce. Bacterial autofluorescence data regarding the illuminated portion of the target and the area around the target is collected and analyzed to determine bacterial load of the illuminated portion of the target and area around the target. The autofluorescence data may be analyzed using pixel intensity. Changes in bacterial load of the target over time may be tracked. The target may be a wound in tissue.
Abstract: A locking member for a gate apparatus comprises a body mountable to a gripping array of a support, said body having a mating form mutually engageable with the gripping array, whereby axial motion of said body relative to said gripping array is inhibited. A member extends away from said body, said member defining a cross-tie mount for receiving a mating end of a cross-tie. The cross-tie mount has a cross-tie end retainer which is movable between a first position securing said cross-tie in said cross-tie mount, and a second position permitting release of said cross-tie from said cross-tie mount, whereby the cross-tie may be moved to function as a gate.
Type:
Grant
Filed:
March 7, 2017
Date of Patent:
September 10, 2019
Assignee:
University Health Network
Inventors:
Andrew John Hart, Geoffrey Roy Fernie, T. Daniel Smyth, Victoria P. Komisar, Emily Catherine King, Peter George Murray
Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
Type:
Grant
Filed:
February 1, 2018
Date of Patent:
August 27, 2019
Assignee:
University Health Network
Inventors:
Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
Type:
Grant
Filed:
February 22, 2018
Date of Patent:
July 23, 2019
Assignee:
University Health Network
Inventors:
Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
Abstract: A biocompatible, electrically conductive biomaterial capable of earn carrying the electrical potential of a cardiac impulse and comprising (1) a conductive polymer such as polyaniline, polypyrrole or polythiophene, and (ii) a biocompatible component such as a polysaccharide, a protein, or a polypeptide, in particular chitosan or gelatin, is described. The material can take the form of a hydrogel, membrane, sheet or mesh. It can be used to restore or improve electrical impulse propagation across damaged tissue or scar region of the myocardium, in particular in the ti treatment of myocardial infarction and arrhythmia.
Abstract: A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a photodynamic compound containing at least one transition metal; and (b) irradiating the photodynamic compound in the organism with electromagnetic radiation, wherein the electromagnetic radiation includes ionizing radiation and is effective to activate the photodynamic compound to destroy at least one of the cells and the microorganisms in the organism. The ionizing radiation is preferably X-rays and/or gamma rays. The non-ionizing radiation is preferably light in the range from 600-950 nm.
Type:
Grant
Filed:
April 20, 2017
Date of Patent:
July 2, 2019
Assignees:
THERALASE TECHNOLOGIES, INC., UNIVERSITY HEALTH NETWORK
Inventors:
Arkady Mandel, Carl Fisher, Lothar Lilge
Abstract: Disclosed herein are chimeric antigen receptors (CARs) comprising an intracellular segment comprising an interleukin receptor chain, a JAK-binding motif, a Signal Transducer and Activator of Transcription (STAT) 5 association motif and/or a CD3? intracellular signaling domain comprising an exogenous STAT3 association motif, as well as cells and 5 compositions comprising said CARs and uses thereof.
Type:
Grant
Filed:
February 11, 2016
Date of Patent:
July 2, 2019
Assignees:
University Health Network, Takara Bio Inc.